ECEESPE2025 Poster Presentations Pituitary, Neuroendocrinology and Puberty (162 abstracts)
Long-term safety and efficacy of once-daily oral paltusotine in the treatment of patients with acromegaly: ACROBAT advance year 4 analysis
Monica R. Gadelha 1 , Harpal S. Randeva 2 , Murray B. Gordon 3 , Mirjana Doknic 4 , Emese Mezosi 5 , Miklos Toth 6 , Cesar Luiz Boguszewski 7 , Christopher Davidson 8 , Alessandra Casagrande 8 , Martin Bidlingmaier 9 , Christian J. Strasburger 10 & Alan Krasner 8
1Neuroendocrinology Research Center/Endocrinology Division—Medical School and Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 2University Hospitals Coventry and Warwickshire NHS Trust, and Division of Biomedicine, Warwick Medical School, University of Warwick, Coventry, United Kingdom; 3Allegheny Neuroendocrinology Center, Allegheny General Hospital, Pittsburgh, United States; 4Neuroendocrine Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 5Department of Medicine, University of Pécs Medical School, Pécs, Hungary; 6Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary; 7Department of Internal Medicine, Endocrine Division (SEMPR), University Hospital, Federal University of Paraná, Curitiba, Brazil; 8Crinetics Pharmaceuticals Inc., San Diego, United States; 9Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany; 10Department of Medicine for Endocrinology and Metabolism, Charité Universitaetsmedizin, Campus Mitte, Berlin, Germany
JOINT3567
Background: Paltusotine is a non-peptide, highly selective SST2 receptor agonist in development as a once-daily, oral treatment for acromegaly and carcinoid syndrome. This long-term analysis of safety and efficacy of paltusotine includes patients with acromegaly who have been followed for up to approximately 4 years.
Methods: ACROBAT Advance is an ongoing, single-arm, open-label extension study of paltusotine in patients with acromegaly. Enrolled patients had completed either ACROBAT Edge or Evolve phase 2 parent studies. In Edge, at enrollment all patients were candidates for combination drug therapy: either sub-optimally controlled on an injected SRL (octreotide or lanreotide) alone or in combination with cabergoline, or required combination therapy or pasireotide to achieve normal IGF-I levels. In Evolve, enrolled patients had normal IGF-I levels on injected SRL monotherapy. When the Advance study was initiated, paltusotine was formulated as a capsule (dose range, 10-40 mg); all patients were switched to the tablet formulation (dose range, 20-60 mg) during year 3 of the study. Adjunctive treatment with cabergoline or pegvisomant was allowed in patients who did not attain normal IGF-I levels on the maximum dose of paltusotine.
Results: Forty-three patients were enrolled in Advance (Edge, n = 32; Evolve, n = 11; 88% of eligible patients): at baseline, mean±SD age 53.0±11.6 years, 56% female, 86% previous pituitary surgery, and no prior radiotherapy. IGF-I control in Edge and Evolve subsets remained stable at parent study baseline values. For all patients pooled, median (IQR) IGF-I levels were 1.15× ULN (0.84-1.46; n = 43) at parent study baseline; in Advance, 1.14× ULN (0.89-1.29; n = 40), 1.07× ULN (0.91-1.30; n = 37), 1.02× ULN (0.83-1.21; n = 33), and 1.01× ULN (0.83-1.13; n = 20) at months 12, 24, 36, and 48, respectively. Acromegaly symptoms, as measured using Acromegaly Symptom Diary (score range, 0-70; higher values indicate greater symptom burden), were stably controlled: median (IQR) score of 8.6 (3.6-20.1; n = 21) at parent study baseline; in Advance, 10.5 (5.0-18.5; n = 40), 10.0 (5.0-23.5; n = 36), 11.0 (4.0-26.0; n = 33), and 10.0 (4.0-18.0; n = 20) at months 12, 24, 36, and 48, respectively. Two serious drug-related AEs (cholelithiasis) were reported. Of the 8 patients who discontinued study, 2 were due to AEs (mild or moderate).
Conclusion: Long-term results (up to ~4 years) show that once-daily oral paltusotine treatment was well tolerated, with stable biochemical and symptom control relative to that observed with injected SRLs.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more